Europese Unie - Nederlands - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - neoplasmata van de borst - antineoplastische middelen - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Europese Unie - Nederlands - EMA (European Medicines Agency)

eli lilly nederland b.v. - galcanezumab - migraine stoornissen - analgesics, galcanezumab - emgality is geïndiceerd voor de profylaxe van migraine bij volwassenen die minstens 4 dagen migraine, - per maand.

Europese Unie - Nederlands - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastische middelen - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Europese Unie - Nederlands - EMA (European Medicines Agency)

eli lilly nederland b.v. - tirzepatide - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 en 5.

Europese Unie - Nederlands - EMA (European Medicines Agency)

eli lilly nederland b.v. - lasmiditan succinate - migraine stoornissen - pijnstillers - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Europese Unie - Nederlands - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - colitis, ulcerative - immunosuppressiva - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Europese Unie - Nederlands - EMA (European Medicines Agency)

eli lilly nederland b.v. - pirtobrutinib - lymfoom, mantel-cel - proteïne kinase remmers - treatment of mantle cell lymphoma (mcl).

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

theramex ireland ltd. - ganirelixacetaat 0,27 mg/0,5 ml - eq. ganirelix 0,25 mg/0,5 ml - oplossing voor injectie in een voorgevulde spuit - ganirelix

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

triptorelinepamoaat 31 mg/flacon samenstelling overeenkomend met ; triptoreline 22,5 mg/flacon - poeder en oplosmiddel voor suspensie voor injectie met verlengde afgifte - carmellose natrium (e 466) ; mannitol (d-) (e 421) ; melkzuur (d,l)-glycolzuur copolymeer laurylester ; melkzuur(d,l)-glycolzuur copolymeer ; polysorbaat 80 (e 433) ; water voor injectie

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

triptorelinepamoaat 31 mg/flacon samenstelling overeenkomend met ; triptoreline 22,5 mg/flacon - poeder en oplosmiddel voor suspensie voor injectie met verlengde afgifte - carmellose natrium (e 466) ; mannitol (d-) (e 421) ; melkzuur (d,l)-glycolzuur copolymeer laurylester ; melkzuur(d,l)-glycolzuur copolymeer ; polysorbaat 80 (e 433) ; stikstof (head space) (e 941) ; water voor injectie